Nephros, Inc. (NASDAQ:NEPH)

Nephros, Inc. primarily develops hemodiafiltration (HDF) products and technologies for treating patients with end stage renal disease (ESRD). The company also offers OLpur HD 190 high-flux dialyzer cartridge for use with hemodialysis or HDF machines. It has three products in various stages of development in HDF modality to deliver therapy to ESRD patients, which include OLpur MDHDF filter series consisting of MD190 and MD220 diafilters for HDF therapy; OLpur H2H, an add-on module designed to allow the common types of hemodialysis machines to be used for HDF therapy; and OLpur NS2000 system, a stand-alone HDF machine and associated filter technology. In addition, the company also develops dual stage ultrafilter water filtration system. It markets its products primarily to healthcare providers, such as hospitals, dialysis clinics, managed care organizations, and nephrology physician groups. The company was founded in 1997 and is headquartered in River Edge, New Jersey.

Web site: http://www.nephros.com

Last updated May 11, 2012